Clinical review: Distinguishing constitutional delay of growth and puberty from isolated hypogonadotropic hypogonadism: critical appraisal of available diagnostic tests - PubMed (original) (raw)
Review
. 2012 Sep;97(9):3056-67.
doi: 10.1210/jc.2012-1598. Epub 2012 Jun 20.
Affiliations
- PMID: 22723321
- DOI: 10.1210/jc.2012-1598
Review
Clinical review: Distinguishing constitutional delay of growth and puberty from isolated hypogonadotropic hypogonadism: critical appraisal of available diagnostic tests
Jennifer Harrington et al. J Clin Endocrinol Metab. 2012 Sep.
Abstract
Context: Determining the etiology of delayed puberty during initial evaluation can be challenging. Specifically, clinicians often cannot distinguish constitutional delay of growth and puberty (CDGP) from isolated hypogonadotropic hypogonadism (IHH), with definitive diagnosis of IHH awaiting lack of spontaneous puberty by age 18 yr. However, the ability to make a timely, correct diagnosis has important clinical implications.
Objective: The aim was to describe and evaluate the literature regarding the ability of diagnostic tests to distinguish CDGP from IHH.
Evidence acquisition: A PubMed search was performed using key words "puberty, delayed" and "hypogonadotropic hypogonadism," and citations within retrieved articles were reviewed to identify studies that assessed the utility of basal and stimulation tests in the diagnosis of delayed puberty. Emphasis was given to a test's ability to distinguish prepubertal adolescents with CDGP from those with IHH.
Evidence synthesis: Basal gonadotropin and GnRH stimulation tests have limited diagnostic specificity, with overlap in gonadotropin levels between adolescents with CDGP and IHH. Stimulation tests using more potent GnRH agonists and/or human chorionic gonadotropin may have better discriminatory value, but small study size, lack of replication of diagnostic thresholds, and prolonged protocols limit clinical application. A single inhibin B level in two recent studies demonstrated good differentiation between groups.
Conclusion: Distinguishing IHH from CDGP is an important clinical issue. Basal inhibin B may offer a simple, discriminatory test if results from recent studies are replicated. However, current literature does not allow for recommendation of any diagnostic test for routine clinical use, making this an important area for future investigation.
Similar articles
- Inhibin B plus LH vs GnRH agonist test for distinguishing constitutional delay of growth and puberty from isolated hypogonadotropic hypogonadism in boys.
Binder G, Schweizer R, Blumenstock G, Braun R. Binder G, et al. Clin Endocrinol (Oxf). 2015 Jan;82(1):100-5. doi: 10.1111/cen.12613. Epub 2014 Oct 23. Clin Endocrinol (Oxf). 2015. PMID: 25207430 - Basal follicle-stimulating hormone and peak gonadotropin levels after gonadotropin-releasing hormone infusion show high diagnostic accuracy in boys with suspicion of hypogonadotropic hypogonadism.
Grinspon RP, Ropelato MG, Gottlieb S, Keselman A, Martínez A, Ballerini MG, Domené HM, Rey RA. Grinspon RP, et al. J Clin Endocrinol Metab. 2010 Jun;95(6):2811-8. doi: 10.1210/jc.2009-2732. Epub 2010 Apr 6. J Clin Endocrinol Metab. 2010. PMID: 20371659 - Current clinical management of constitutional delay of growth and puberty.
Gaudino R, De Filippo G, Bozzola E, Gasparri M, Bozzola M, Villani A, Radetti G. Gaudino R, et al. Ital J Pediatr. 2022 Mar 24;48(1):45. doi: 10.1186/s13052-022-01242-5. Ital J Pediatr. 2022. PMID: 35331309 Free PMC article. Review. - Pubertal delay: the challenge of a timely differential diagnosis between congenital hypogonadotropic hypogonadism and constitutional delay of growth and puberty.
Bollino A, Cangiano B, Goggi G, Federici S, Duminuco P, Giovanelli L, Galazzi E, Vezzoli V, Persani L, Bonomi M. Bollino A, et al. Minerva Pediatr. 2020 Aug;72(4):278-287. doi: 10.23736/S0026-4946.20.05860-0. Epub 2020 May 15. Minerva Pediatr. 2020. PMID: 32418410 Review.
Cited by
- Diagnosing and treating anterior pituitary hormone deficiency in pediatric patients.
Rey RA, Bergadá I, Ballerini MG, Braslavsky D, Chiesa A, Freire A, Grinspon RP, Keselman A, Arcari A. Rey RA, et al. Rev Endocr Metab Disord. 2024 Jun;25(3):555-573. doi: 10.1007/s11154-023-09868-4. Epub 2023 Dec 19. Rev Endocr Metab Disord. 2024. PMID: 38112850 Review. - Outcomes and experiences of adults with congenital hypogonadism can inform improvements in the management of delayed puberty.
Howard SR, Quinton R. Howard SR, et al. J Pediatr Endocrinol Metab. 2023 Nov 24;37(1):1-7. doi: 10.1515/jpem-2023-0407. Print 2024 Jan 29. J Pediatr Endocrinol Metab. 2023. PMID: 37997801 Free PMC article. Review. - Key features of puberty onset and progression can help distinguish self-limited delayed puberty from congenital hypogonadotrophic hypogonadism.
Aung Y, Kokotsis V, Yin KN, Banerjee K, Butler G, Dattani MT, Dimitri P, Dunkel L, Hughes C, McGuigan M, Korbonits M, Paltoglou G, Sakka S, Shah P, Storr HL, Willemsen RH, Howard SR. Aung Y, et al. Front Endocrinol (Lausanne). 2023 Aug 28;14:1226839. doi: 10.3389/fendo.2023.1226839. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37701896 Free PMC article. - The Emerging Therapeutic Potential of Kisspeptin and Neurokinin B.
Patel B, Koysombat K, Mills EG, Tsoutsouki J, Comninos AN, Abbara A, Dhillo WS. Patel B, et al. Endocr Rev. 2024 Jan 4;45(1):30-68. doi: 10.1210/endrev/bnad023. Endocr Rev. 2024. PMID: 37467734 Free PMC article. Review. - A case of novel mutation in ANOS1 (KAL1) gene and review of Kallmann syndrome.
Arora S, Yeliosof O, Chin VL. Arora S, et al. Endocrinol Diabetes Metab Case Rep. 2023 Jun 9;2023(2):22-0310. doi: 10.1530/EDM-22-0310. Print 2023 Jun 1. Endocrinol Diabetes Metab Case Rep. 2023. PMID: 37294556 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical